Renovation and expansion of BSL3 and ABSL3 facilities

描述(由申请人提供)： 宾夕法尼亚大学医学院提议扩大BSL3实验室的能力，并翻新现有的BSL2间隔室，使其达到BSL3标准，以适应NIH资助的新兴传染病和生物防御研究的快速增长，这支持了宾夕法尼亚大学大量研究人员的工作。虽然近年来研究和隔膜空间都得到了极大的扩展，但新的BSL3设施的建设没有跟上医学院在新出现的传染病和艾滋病毒方面的研究和研究培训出人意料的快速增长。宾夕法尼亚大学的研究人员在中大西洋地区生物防御和新发传染病研究卓越中心(RCE)中发挥着重要作用，持有NIH关于新发传染病的培训补助金，持有授予的研究补助金，支持西尼罗河、SARS、埃博拉、耶尔斯尼亚猪瘟、炭疽、克里米亚刚果出血热病毒和痘病毒的工作，并获得赠款支持新发传染病病原体的工作。宾夕法尼亚大学关于新出现的传染病和艾滋病毒的研究受到有限的第三方能力的极大限制。医学院只有一个通用的BSL3实验室。该设施于2000年开业，已被大量用户淹没。此外，宾夕法尼亚大学没有一家动物BSL3(ABSL3)设施。因此，宾夕法尼亚大学的调查人员不能使用BSL3试剂进行小动物研究。为了使宾夕法尼亚大学的调查人员能够继续扩大他们在新出现的传染病病原体、生物防御和艾滋病毒方面的工作，我们提议建造一个新的500平方英尺。英国《金融时报》BSL3实验室，翻新我们主要的BSL3设施，并将其规模扩大一倍，并将ABSL2设施改造成现代化的ABSL3设施。

DESCRIPTION (provided by applicant): The University of Pennsylvania School of Medicine proposes to expand BSL3 laboratory capacity and to renovate an existing BSL2 vivarium, bringing it to BSL3 standards, to accommodate the rapid growth in NIHfunded research for emerging infectious diseases and biodefense that supports the work by a large number of Penn investigators. While both research and vivarium space have been greatly expanded in recent years, construction of new BSL3 facilities have not kept pace with the unexpectedly rapid growth in research and research training on emerging infectious diseases and HIV at the School of Medicine. Penn investigators play a major role in the Middle Atlantic Regional Center of Excellence (RCE) for Biodefense and Emerging Infectious Diseases Research, hold an NIH training grant on Emerging Infectious Diseases, hold awarded research grants that support work on West Nile, SARS, Ebola, Yersiniapestis, Anthrax, Crimean Congo Hemorrhagic fever virus and poxviruses, and have grants to support work on emerging infectious agents. Research at Penn on emerging infectious diseases and, to a lesser extent HIV, is greatly constrained by limited BSL3 capacity. There is only a single, common use BSL3 laboratory at the School of Medicine. This facility opened in 2000, and has been overwhelmed by large numbers of users. In addition, there is not a single animal BSL3 (ABSL3) facility at Penn. As a result, Penn investigators cannot perform small animal studies with BSL3 agents. To make it possible for Penn investigators to continue to expand their work on emerging infectious agents, biodefense and HIV, we propose to construct a new 500 sq. ft. BSL3 laboratory, renovate and double the size of our major BSL3 facility, and convert an ABSL2 into a modern ABSL3 facility.